Korea Bio-Gen Co.Ltd (318000) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Korea Bio-Gen Co.Ltd (318000) has a cash flow conversion efficiency ratio of 0.003x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩145.77 Million ≈ $98.79K USD) by net assets (₩47.16 Billion ≈ $31.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Korea Bio-Gen Co.Ltd to measure how much of total assets are equity-financed.
Korea Bio-Gen Co.Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Korea Bio-Gen Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 318000 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Korea Bio-Gen Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Korea Bio-Gen Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Spackman Equit
V:SQG
|
0.040x |
|
Connection Technology Systems
TWO:3672
|
-0.009x |
|
Mstns Co.Ltd
KQ:257370
|
-0.108x |
|
Skandia Greenpower AS
OL:SKAND
|
0.054x |
|
Edesa Holding SA
BA:EDSH
|
0.067x |
|
Bakrie Sumatera Plantations
JK:UNSP
|
-0.021x |
|
Great Western Mining Corp Plc
IR:8GW
|
-0.028x |
|
Safestore Holdings Plc
LSE:SAFE
|
0.026x |
Annual Cash Flow Conversion Efficiency for Korea Bio-Gen Co.Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of Korea Bio-Gen Co.Ltd from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Korea Bio-Gen Co.Ltd (318000) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩46.93 Billion ≈ $31.80 Million |
₩7.34 Billion ≈ $4.97 Million |
0.156x | +63.74% |
| 2024-12-31 | ₩44.91 Billion ≈ $30.44 Million |
₩4.29 Billion ≈ $2.91 Million |
0.096x | -57.57% |
| 2023-12-31 | ₩42.05 Billion ≈ $28.50 Million |
₩9.47 Billion ≈ $6.42 Million |
0.225x | +371.25% |
| 2022-12-31 | ₩34.95 Billion ≈ $23.68 Million |
₩1.67 Billion ≈ $1.13 Million |
0.048x | -51.19% |
| 2021-12-31 | ₩31.61 Billion ≈ $21.42 Million |
₩3.09 Billion ≈ $2.10 Million |
0.098x | +6.83% |
| 2020-12-31 | ₩28.16 Billion ≈ $19.09 Million |
₩2.58 Billion ≈ $1.75 Million |
0.092x | -22.91% |
| 2019-12-31 | ₩25.69 Billion ≈ $17.41 Million |
₩3.05 Billion ≈ $2.07 Million |
0.119x | -34.28% |
| 2018-12-31 | ₩10.97 Billion ≈ $7.44 Million |
₩1.98 Billion ≈ $1.34 Million |
0.181x | +16.60% |
| 2017-12-31 | ₩8.93 Billion ≈ $6.05 Million |
₩1.38 Billion ≈ $938.31K |
0.155x | -- |
About Korea Bio-Gen Co.Ltd
KBG Corp. produces and supplies a range of fine chemicals in South Korea and internationally. The company offers silicone chemicals, such as functional organosilanes, functional silicone polymers, silicone resins and intermediates, silicone pressure sensitive adhesives, and silicone materials for electronics; specialty chemicals, including polymerization inhibitors; and food additives, as well as… Read more